GEM132 antisense oligonucleotide with modified RNA caps to increase metabolic stability data

HYBN reported Phase I results, showing tolerability and

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE